Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
On 29 April 2025, ADI Regional Director for the Americas, Diego Aguilar attended the Symposium on Brain Health Promotion: Towards a National Dementia Plan in Buenos Aires, Argentina, during which key political figures, international experts, civil society leaders, and advocates joined the call for the urgent approval of Argentina’s first National Dementia Plan.
This month, ADI staff and representatives took part in important activity in the European region. ADI Regional Director for the Americas, Diego Aguilar, travelled to Madrid to attend the Triangular Cooperation Seminar, organised by the European Union's ADELANTE 2 Programme. ADI Head of Membership, Laura Aubert, visited ADI’s member in Czechia and attended the 19th World Congress on Controversies in Neurology in Prague. Then, ADI staff attended the World Dementia Council meeting in London for the 2025 Summit. We round off this blog by celebrating the co-founder of ADI’s member in Russia, Alzrus, Alexandra Shchetkina, for her nomination for the most prestigious Russian educational award - the Knowledge Prize.
In late March, ADI CEO Paola Barbarino travelled to St. Paul’s Bay, Malta to give a keynote address to the Empowering Minds: Innovation and Compassion in Dementia Care symposium hosted by the Dementia Care Directorate, Active Ageing and Community Care. This symposium focused on the symbiosis between advocacy and advancement within dementia care and research.
This month, ADI CEO Paola Barbarino and ADI Director of Research and Publications, Wendy Weidner, travelled to the East Coast of the United States to meet with leading researchers, universities, and industry innovators to discuss recent advancements in the research and innovation sphere of dementia care.
February saw a flurry of dementia-related activity within the European region. Sweden has updated their national dementia strategy from 2018; ADI’s Head of Membership attended a session at the Belgian Senate; as part of their efforts to raise the profile of those living with dementia; ADI CEO Paola Barbarino virtually opened the 14th Panhellenic Conference on Alzheimer's Disease, organized by ADI’s member in Greece, Panhellenic Federation of Alzheimer’s Disease and Related Disorders, and ADI is partaking in the public hearings for the development of the WHO Second European Program of Work.
In February, ADI representatives took part in two important events in the Americas showcasing the great progress currently being made in the region.ADI Board Member Rosa Farrés attended a workshop in Peru on Advancing Brain Health, hosted by the Global Brain Health Institute at the beginning of the month. Then, ADI Regional Director for the Americas, Diego Aguilar, visited Chile to attend the Alzheimer’s Association International Conference (AAIC) Neuroscience Next conference, building on Chile’s recent efforts on the updating of their National Dementia Plan strategy.